• Slide

    PCa Europe 2017

    Tuesday 24th January 2017, Brussels

  • Slide

    PCa Europe 2017

    Tuesday 24th January 2017, Brussels

  • Slide

    PCa Europe 2017

    Tuesday 24th January 2017, Brussels

  • Slide

    PCa Europe 2017

    Tuesday 24th January 2017, Brussels

  • Slide

    PCa Europe 2017

    Tuesday 24th January 2017, Brussels

  • Slide

    PCa Europe 2017

    Tuesday 24th January 2017, Brussels

  • Slide

    PCa Europe 2017

    Tuesday 24th January 2017, Brussels

  • Slide

    PCa Europe 2017

    Tuesday 24th January 2017, Brussels

  • Slide

    PCa Europe 2017

    Tuesday 24th January 2017, Brussels

Prostate cancer (PCa) is the second leading cause of cancer death in men in Europe.

The incidence of prostate cancer has increased considerably over the last two decades and continued growth is expected, due to an aging population. This continued high prevalence will place even greater burden on healthcare services and expenditure, throughout Europe, over the coming years.

The EU must raise greater awareness of prostate cancer, highlighting the risk factors and symptoms and promoting healthier lifestyles, as a preventive measure.

Continued investment in clinical research and innovation is essential for improving diagnostic accuracy and developing novel therapeutic approaches, which could help to improve the overall management of PCa in Europe.

This Roundtable meeting will bring together EU policy makers, medical and clinical professionals, academic experts, healthcare players and patient groups, to examine the ongoing challenges in managing prostate cancer more effectively and explore practical solutions in order to reach an EU-wide consensus and implement a forward action plan.

At this Roundtable, participants will hear from high level EU health officials and leading oncology experts, offering a variety of perspectives and recommendations, through a series of open discussions.

Subjects to be addressed include:
  • Potential for an EU-Wide Population-Based Screening Programme
  • Patient satisfaction measures and improving patient experience
  • Accuracy of Current Diagnostic Techniques to Identify Low-Risk and High-Risk Prostate Cancer
  • New Developments in Immunotherapy of Prostate Cancer
  • Reducing Incidences of Over-Detection and Over-Treatment
  • Surgery, Radiotherapy and Brachytherapy – reducing recovery times
  • Advances in Radical Prostatectomy, Hormone Therapy and Chemotherapy
  • Chemotherapy, Immunotherapy, Bone targeted therapies and Radium-223
  • Prostate Cancer Management in Senior Adults: A Call to Action
  • Holistic Personalised Management to Improve Quality of Life
  • Improving treatment across countries – areas of improvement
  • The role of e-health and mobile health in managing and receiving information
Networking

The Roundtable will also provide hours of networking time, including coffee breaks, lunch, and a drinks reception to ensure participants have the maximum possible time to establish and stregthen relationships, whilst exchanging ideas.